Mistakes in mouse models of nonalcoholic steatophepatitis and how to avoid them

Filters:

UEG Mistakes In Articles

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Mistakes in mouse models of nonalcoholic steatophepatitis and how to avoid them

Rui Castro

Summary

AI Generated

Nonalcoholic fatty liver disease is a growing cause of chronic liver disease worldwide, with NASH posing substantially higher risk of progression to cirrhosis and hepatocellular carcinoma than NAFL, and is expected to become the leading cause of end-stage liver disease in coming decades.

NAFLD can manifest as nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH), with NASH carrying substantially higher risk of progression to advanced liver disease, cirrhosis, and hepatocellular carcinoma compared with NAFL.
There is currently a lack of directed pharmacological therapies for NAFLD.
NAFLD has complex, multifactorial disease aetiology and pathology.
NAFLD is expected to become the leading cause of end-stage liver disease in the coming decades.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes

References

Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10

Kaur S, Kidambi S, Ortega-Ribera M, et al. In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. Cellular and Molecular Gastroenterology and Hepatology 2023; 15: 559–571.

Rezvani M, Vallier L, Guillot A. Modeling Nonalcoholic Fatty Liver Disease in the Dish Using Human-Specific Platforms: Strategies and Limitations. Cellular and Molecular Gastroenterology and Hepatology 2023; 15: 1135–1145.

Feaver RE, Cole BK, Lawson MJ, et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight; 1. Epub ahead of print 8 December 2016. DOI: 10.1172/jci.insight.90954.

Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908–922.

Haas JT, Francque S, Staels B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu Rev Physiol 2016; 78: 181–205.

Haczeyni F, Yeh MM, Ioannou GN, et al. Mouse models of non‐alcoholic steatohepatitis: A reflection on recent literature. J of Gastro and Hepatol 2018; 33: 1312–1320.

Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obesity Metabolism 2021; 23: 1069–1083.

Gallage S, Avila JEB, Ramadori P, et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab 2022; 4: 1632–1649.

Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22: 1707–1718.

10.

Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes. Cancer Cell 2014; 26: 549–564.

11.

Mann JP, Semple RK, Armstrong MJ. How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease? Front Endocrinol; 7. Epub ahead of print 16 November 2016. DOI: 10.3389/fendo.2016.00145.

12.

Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. Journal of Hepatology 2018; 68: 230–237.

13.

Ibrahim SH, Hirsova P, Malhi H, et al. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016; 61: 1325–1336.

14.

Kakimoto PA, Kowaltowski AJ. Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biology 2016; 8: 216–225.

15.

Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014; 25: 473–486.

16.

Wang M-E, Singh BK, Hsu M-C, et al. Increasing Dietary Medium-Chain Fatty Acid Ratio Mitigates High-fat Diet-Induced Non-Alcoholic Steatohepatitis by Regulating Autophagy. Sci Rep 2017; 7: 13999.

17.

Arsov T, Larter CZ, Nolan CJ, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochemical and Biophysical Research Communications 2006; 342: 1152–1159.

18.

Bell-Anderson KS, Aouad L, Williams H, et al. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. Int J Obes 2011; 35: 1539–1548.

19.

Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of Hepatology 2016; 65: 579–588.

20.

Ganz M. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. WJG 2014; 20: 8525.

21.

Stöppeler S, Palmes D, Fehr M, et al. Gender and strain-specific differences in the development of steatosis in rats. Lab Anim 2013; 47: 43–52.

22.

Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol 2013; 46: 141–152.

23.

Matsushita N, Hassanein MT, Martinez-Clemente M, et al. Gender difference in NASH susceptibility: Roles of hepatocyte Ikkβ and Sult1e1. PLoS ONE 2017; 12: e0181052.

24.

Yatsuji S, Hashimoto E, Tobari M, et al. Influence of age and gender in Japanese patients with non‐alcoholic steatohepatitis. Hepatology Research 2007; 37: 1034–1043.

25.

De Lédinghen V, Ratziu V, Causse X, et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. Journal of Hepatology 2006; 45: 592–599.

26.

Louet J-F, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: Insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6: 180–185.

27.

Saglam K, Polat Z, Yilmaz MI, et al. Effects of Postmenopausal Hormone Replacement Therapy on Insulin Resistance. ENDO 2002; 18: 211–214.

28.

Wooden B, Goossens N, Hoshida Y, et al. Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 2017; 152: 53-67.e3.

29.

Teufel A, Itzel T, Erhart W, et al. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. Gastroenterology 2016; 151: 513-525.e0.

30.

Hansen HH, Ægidius HM, Oró D, et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020; 20: 210.

31.

Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. Journal of Hepatology 2018; 69: 385–395.

32.

Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. Journal of Hepatology 2018; 69: 272–274.

33.

Omary MB, Cohen DE, El‐Omar EM, et al. Not all mice are the same: Standardization of animal research data presentation. Hepatology 2016; 63: 1752–1754.

34.

Bebarta V, Luyten D, Heard K. Emergency Medicine Animal Research: Does Use of Randomization and Blinding Affect the Results? Academic Emergency Medicine 2003; 10: 684–687.

35.

Kuper CF, Vogels J, Kemmerling J, et al. Integrated analysis of toxicity data of two pharmaceutical immunosuppressants and two environmental pollutants with immunomodulating properties to improve the understanding of side effects—A toxicopathologist׳s view. European Journal of Pharmacology 2015; 759: 343–355.

36.

Holman C, Piper SK, Grittner U, et al. Where Have All the Rodents Gone? The Effects of Attrition in Experimental Research on Cancer and Stroke. PLoS Biol 2016; 14: e1002331.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide that can manifest as nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH). Compared with NAFL, NASH poses a substantially higher risk of progression to advanced liver disease, cirrhosis and hepatocellular carcinoma (HCC). Given the lack of directed pharmacological therapies and the complex, multifactorial disease aetiology and pathology, NAFLD is expected to become the leading cause of end-stage liver disease in the coming decades.

Topics

Hepatobiliary

Citation

Castro RE and Diehl AM. Mistakes in animal models of nonalcoholic steatohepatitis and how to avoid them. UEG Education 2018; 18: 30–34

Published

2024

More Like This:

Ian Gralnek on UEG Week 2024

Egle Dieninyte - Misiune

Mistakes in microscopic colitis and how to avoid them

Andreas Münch

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre

Mistakes in cases on call and how to avoid them

Marine Camus

UEG Podcast Episode

UEG Podcast

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Ian Gralnek on UEG Week 2024

Ian Mark Gralnek, Egle Dieninyte - Misiune

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Topics

Endoscopy

Published

2025

More Like This:

Ian Gralnek on UEG Week 2024

Egle Dieninyte - Misiune

Mistakes in microscopic colitis and how to avoid them

Andreas Münch

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre

Mistakes in cases on call and how to avoid them

Marine Camus

UEG Mistakes In Articles

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Mistakes in microscopic colitis and how to avoid them

Andreas Münch

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

References

Mistakes

References

Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10

Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908–922.

Haas JT, Francque S, Staels B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu Rev Physiol 2016; 78: 181–205.

Haczeyni F, Yeh MM, Ioannou GN, et al. Mouse models of non‐alcoholic steatohepatitis: A reflection on recent literature. J of Gastro and Hepatol 2018; 33: 1312–1320.

Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obesity Metabolism 2021; 23: 1069–1083.

Gallage S, Avila JEB, Ramadori P, et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab 2022; 4: 1632–1649.

Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22: 1707–1718.

10.

11.

12.

Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. Journal of Hepatology 2018; 68: 230–237.

13.

Ibrahim SH, Hirsova P, Malhi H, et al. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016; 61: 1325–1336.

14.

Kakimoto PA, Kowaltowski AJ. Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biology 2016; 8: 216–225.

15.

Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014; 25: 473–486.

16.

Wang M-E, Singh BK, Hsu M-C, et al. Increasing Dietary Medium-Chain Fatty Acid Ratio Mitigates High-fat Diet-Induced Non-Alcoholic Steatohepatitis by Regulating Autophagy. Sci Rep 2017; 7: 13999.

17.

Arsov T, Larter CZ, Nolan CJ, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochemical and Biophysical Research Communications 2006; 342: 1152–1159.

18.

19.

Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of Hepatology 2016; 65: 579–588.

20.

Ganz M. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. WJG 2014; 20: 8525.

21.

Stöppeler S, Palmes D, Fehr M, et al. Gender and strain-specific differences in the development of steatosis in rats. Lab Anim 2013; 47: 43–52.

22.

23.

Matsushita N, Hassanein MT, Martinez-Clemente M, et al. Gender difference in NASH susceptibility: Roles of hepatocyte Ikkβ and Sult1e1. PLoS ONE 2017; 12: e0181052.

24.

Yatsuji S, Hashimoto E, Tobari M, et al. Influence of age and gender in Japanese patients with non‐alcoholic steatohepatitis. Hepatology Research 2007; 37: 1034–1043.

25.

26.

Louet J-F, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: Insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6: 180–185.

27.

Saglam K, Polat Z, Yilmaz MI, et al. Effects of Postmenopausal Hormone Replacement Therapy on Insulin Resistance. ENDO 2002; 18: 211–214.

28.

Wooden B, Goossens N, Hoshida Y, et al. Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 2017; 152: 53-67.e3.

29.

30.

Hansen HH, Ægidius HM, Oró D, et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020; 20: 210.

31.

32.

Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. Journal of Hepatology 2018; 69: 272–274.

33.

Omary MB, Cohen DE, El‐Omar EM, et al. Not all mice are the same: Standardization of animal research data presentation. Hepatology 2016; 63: 1752–1754.

34.

Bebarta V, Luyten D, Heard K. Emergency Medicine Animal Research: Does Use of Randomization and Blinding Affect the Results? Academic Emergency Medicine 2003; 10: 684–687.

35.

36.

Holman C, Piper SK, Grittner U, et al. Where Have All the Rodents Gone? The Effects of Attrition in Experimental Research on Cancer and Stroke. PLoS Biol 2016; 14: e1002331.

Abstract

Microscopic colitis is an inflammatory bowel disease (IBD) that leads to chronic, watery diarrhoea. First believed to be rare, microscopic colitis has received more attention in recent decades, resulting in increasing incidence rates that exceed those of classic IBD in some countries. Hopefully, it is common practice nowadays to refer patients with chronic diarrhoea for a colonoscopy with biopsy samples taken, as this is the only way to diagnose microscopic colitis. Histology results distinguish between the subtypes of microscopic colitis — lymphocytic colitis, collagenous colitis and the more recently introduced incomplete microscopic colitis.

Topics

IBD

Citation

Münch A. Mistakes in microscopic colitis and how to avoid them. UEG Education 2021; 21: 10–13.

Published

2021

More Like This:

Ian Gralnek on UEG Week 2024

Egle Dieninyte - Misiune

Mistakes in microscopic colitis and how to avoid them

Andreas Münch

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre

Mistakes in cases on call and how to avoid them

Marine Camus

UEG Mistakes In Articles

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

References

Mistakes

References

Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10

Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908–922.

Haas JT, Francque S, Staels B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu Rev Physiol 2016; 78: 181–205.

Haczeyni F, Yeh MM, Ioannou GN, et al. Mouse models of non‐alcoholic steatohepatitis: A reflection on recent literature. J of Gastro and Hepatol 2018; 33: 1312–1320.

Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obesity Metabolism 2021; 23: 1069–1083.

Gallage S, Avila JEB, Ramadori P, et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab 2022; 4: 1632–1649.

Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22: 1707–1718.

10.

11.

12.

Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. Journal of Hepatology 2018; 68: 230–237.

13.

Ibrahim SH, Hirsova P, Malhi H, et al. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016; 61: 1325–1336.

14.

Kakimoto PA, Kowaltowski AJ. Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biology 2016; 8: 216–225.

15.

Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014; 25: 473–486.

16.

Wang M-E, Singh BK, Hsu M-C, et al. Increasing Dietary Medium-Chain Fatty Acid Ratio Mitigates High-fat Diet-Induced Non-Alcoholic Steatohepatitis by Regulating Autophagy. Sci Rep 2017; 7: 13999.

17.

Arsov T, Larter CZ, Nolan CJ, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochemical and Biophysical Research Communications 2006; 342: 1152–1159.

18.

19.

Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of Hepatology 2016; 65: 579–588.

20.

Ganz M. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. WJG 2014; 20: 8525.

21.

Stöppeler S, Palmes D, Fehr M, et al. Gender and strain-specific differences in the development of steatosis in rats. Lab Anim 2013; 47: 43–52.

22.

23.

Matsushita N, Hassanein MT, Martinez-Clemente M, et al. Gender difference in NASH susceptibility: Roles of hepatocyte Ikkβ and Sult1e1. PLoS ONE 2017; 12: e0181052.

24.

Yatsuji S, Hashimoto E, Tobari M, et al. Influence of age and gender in Japanese patients with non‐alcoholic steatohepatitis. Hepatology Research 2007; 37: 1034–1043.

25.

26.

Louet J-F, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: Insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6: 180–185.

27.

Saglam K, Polat Z, Yilmaz MI, et al. Effects of Postmenopausal Hormone Replacement Therapy on Insulin Resistance. ENDO 2002; 18: 211–214.

28.

Wooden B, Goossens N, Hoshida Y, et al. Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 2017; 152: 53-67.e3.

29.

30.

Hansen HH, Ægidius HM, Oró D, et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020; 20: 210.

31.

32.

Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. Journal of Hepatology 2018; 69: 272–274.

33.

Omary MB, Cohen DE, El‐Omar EM, et al. Not all mice are the same: Standardization of animal research data presentation. Hepatology 2016; 63: 1752–1754.

34.

Bebarta V, Luyten D, Heard K. Emergency Medicine Animal Research: Does Use of Randomization and Blinding Affect the Results? Academic Emergency Medicine 2003; 10: 684–687.

35.

36.

Holman C, Piper SK, Grittner U, et al. Where Have All the Rodents Gone? The Effects of Attrition in Experimental Research on Cancer and Stroke. PLoS Biol 2016; 14: e1002331.

Abstract

Barrett’s oesophagus is a premalignant condition of the distal oesophagus predisposing to oesophageal adenocarcinoma. Given the potential for malignant progression and the poor prognosis of eosophageal adenocarcinoma when diagnosed at a symptomatic stage, patients with known Barrett oesophagus undergo regular endoscopic surveillance to detect neoplastic progression at an early and preferably endoscopically, treatable stage. Endoscopic management of early Barrett oesophagus neoplasia consists of a combination of endoscopic imaging, endoscopic resection and endoscopic ablation. Below we discuss a number of mistakes that are frequently made when managing Barrett oesophagus neoplasia and how to avoid them. Much of this discussion draws on existing guidelines (for background reading, check the ESGE Barrett oesophagus guideline), but in many instances the underlying evidence (even in the guideline) is missing and therefore many of our practically driven recommendations are based on common sense and our experience in this field.

Topics

Oesophagus

Citation

Verheij EPD, Pouw RE and Bergman JJ. Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them. UEG Education 2021; 21: 35–39.

Published

2021

More Like This:

Ian Gralnek on UEG Week 2024

Egle Dieninyte - Misiune

Mistakes in microscopic colitis and how to avoid them

Andreas Münch

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre

Mistakes in cases on call and how to avoid them

Marine Camus

UEG Mistakes In Articles

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

References

Mistakes

References

Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10

Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908–922.

Haas JT, Francque S, Staels B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu Rev Physiol 2016; 78: 181–205.

Haczeyni F, Yeh MM, Ioannou GN, et al. Mouse models of non‐alcoholic steatohepatitis: A reflection on recent literature. J of Gastro and Hepatol 2018; 33: 1312–1320.

Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obesity Metabolism 2021; 23: 1069–1083.

Gallage S, Avila JEB, Ramadori P, et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab 2022; 4: 1632–1649.

Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22: 1707–1718.

10.

11.

12.

Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. Journal of Hepatology 2018; 68: 230–237.

13.

Ibrahim SH, Hirsova P, Malhi H, et al. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016; 61: 1325–1336.

14.

Kakimoto PA, Kowaltowski AJ. Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biology 2016; 8: 216–225.

15.

Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014; 25: 473–486.

16.

Wang M-E, Singh BK, Hsu M-C, et al. Increasing Dietary Medium-Chain Fatty Acid Ratio Mitigates High-fat Diet-Induced Non-Alcoholic Steatohepatitis by Regulating Autophagy. Sci Rep 2017; 7: 13999.

17.

Arsov T, Larter CZ, Nolan CJ, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochemical and Biophysical Research Communications 2006; 342: 1152–1159.

18.

19.

Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of Hepatology 2016; 65: 579–588.

20.

Ganz M. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. WJG 2014; 20: 8525.

21.

Stöppeler S, Palmes D, Fehr M, et al. Gender and strain-specific differences in the development of steatosis in rats. Lab Anim 2013; 47: 43–52.

22.

23.

Matsushita N, Hassanein MT, Martinez-Clemente M, et al. Gender difference in NASH susceptibility: Roles of hepatocyte Ikkβ and Sult1e1. PLoS ONE 2017; 12: e0181052.

24.

Yatsuji S, Hashimoto E, Tobari M, et al. Influence of age and gender in Japanese patients with non‐alcoholic steatohepatitis. Hepatology Research 2007; 37: 1034–1043.

25.

26.

Louet J-F, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: Insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6: 180–185.

27.

Saglam K, Polat Z, Yilmaz MI, et al. Effects of Postmenopausal Hormone Replacement Therapy on Insulin Resistance. ENDO 2002; 18: 211–214.

28.

Wooden B, Goossens N, Hoshida Y, et al. Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 2017; 152: 53-67.e3.

29.

30.

Hansen HH, Ægidius HM, Oró D, et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020; 20: 210.

31.

32.

Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. Journal of Hepatology 2018; 69: 272–274.

33.

Omary MB, Cohen DE, El‐Omar EM, et al. Not all mice are the same: Standardization of animal research data presentation. Hepatology 2016; 63: 1752–1754.

34.

Bebarta V, Luyten D, Heard K. Emergency Medicine Animal Research: Does Use of Randomization and Blinding Affect the Results? Academic Emergency Medicine 2003; 10: 684–687.

35.

36.

Holman C, Piper SK, Grittner U, et al. Where Have All the Rodents Gone? The Effects of Attrition in Experimental Research on Cancer and Stroke. PLoS Biol 2016; 14: e1002331.

Abstract

Acute diverticulitis is an inflammatory complication of diverticulosis and can either be uncomplicated or complicated. Making the distinction between uncomplicated and complicated acute diverticulitis is essential because treatment strategies differ between the two. Here, we discuss 10 mistakes frequently made when managing patients with acute diverticulitis. We focus on using the correct terminology, diagnostic preference and several treatment options, such as omitting or administering antibiotics, radiological interventions and various aspects of surgery. Acute diverticulitis is an important topic because its incidence is rising worldwide and it is becoming a considerable burden on healthcare systems. Most of the discussion included here is evidence-based, supplemented with many years’ combined clinical experience where evidence is lacking.

Topics

Endoscopy Radiology & Imaging Surgery

Citation

Cite this article as: Rottier SJ, et al. Mistakes in acute diverticulitis and how to avoid them. UEG Education 2019; 19: 31–35.

Published

2019

More Like This:

Ian Gralnek on UEG Week 2024

Egle Dieninyte - Misiune

Mistakes in microscopic colitis and how to avoid them

Andreas Münch

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre

Mistakes in cases on call and how to avoid them

Marine Camus

UEG Podcast Episode

UEG Podcast

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

From Vienna to Berlin: What inspired us last year at UEG Week

Egle Dieninyte - Misiune, Pradeep Mundre

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Published

2025

More Like This:

Ian Gralnek on UEG Week 2024

Egle Dieninyte - Misiune

Mistakes in microscopic colitis and how to avoid them

Andreas Münch

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre

Mistakes in cases on call and how to avoid them

Marine Camus

UEG Mistakes In Articles

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Mistakes in cases on call and how to avoid them

Xavier Dray, Marine Camus

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

References

Mistakes

References

Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10

Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908–922.

Haas JT, Francque S, Staels B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu Rev Physiol 2016; 78: 181–205.

Haczeyni F, Yeh MM, Ioannou GN, et al. Mouse models of non‐alcoholic steatohepatitis: A reflection on recent literature. J of Gastro and Hepatol 2018; 33: 1312–1320.

Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obesity Metabolism 2021; 23: 1069–1083.

Gallage S, Avila JEB, Ramadori P, et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab 2022; 4: 1632–1649.

Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22: 1707–1718.

10.

11.

12.

Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. Journal of Hepatology 2018; 68: 230–237.

13.

Ibrahim SH, Hirsova P, Malhi H, et al. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016; 61: 1325–1336.

14.

Kakimoto PA, Kowaltowski AJ. Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biology 2016; 8: 216–225.

15.

Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014; 25: 473–486.

16.

Wang M-E, Singh BK, Hsu M-C, et al. Increasing Dietary Medium-Chain Fatty Acid Ratio Mitigates High-fat Diet-Induced Non-Alcoholic Steatohepatitis by Regulating Autophagy. Sci Rep 2017; 7: 13999.

17.

Arsov T, Larter CZ, Nolan CJ, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochemical and Biophysical Research Communications 2006; 342: 1152–1159.

18.

19.

Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of Hepatology 2016; 65: 579–588.

20.

Ganz M. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. WJG 2014; 20: 8525.

21.

Stöppeler S, Palmes D, Fehr M, et al. Gender and strain-specific differences in the development of steatosis in rats. Lab Anim 2013; 47: 43–52.

22.

23.

Matsushita N, Hassanein MT, Martinez-Clemente M, et al. Gender difference in NASH susceptibility: Roles of hepatocyte Ikkβ and Sult1e1. PLoS ONE 2017; 12: e0181052.

24.

Yatsuji S, Hashimoto E, Tobari M, et al. Influence of age and gender in Japanese patients with non‐alcoholic steatohepatitis. Hepatology Research 2007; 37: 1034–1043.

25.

26.

Louet J-F, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: Insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6: 180–185.

27.

Saglam K, Polat Z, Yilmaz MI, et al. Effects of Postmenopausal Hormone Replacement Therapy on Insulin Resistance. ENDO 2002; 18: 211–214.

28.

Wooden B, Goossens N, Hoshida Y, et al. Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 2017; 152: 53-67.e3.

29.

30.

Hansen HH, Ægidius HM, Oró D, et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020; 20: 210.

31.

32.

Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. Journal of Hepatology 2018; 69: 272–274.

33.

Omary MB, Cohen DE, El‐Omar EM, et al. Not all mice are the same: Standardization of animal research data presentation. Hepatology 2016; 63: 1752–1754.

34.

Bebarta V, Luyten D, Heard K. Emergency Medicine Animal Research: Does Use of Randomization and Blinding Affect the Results? Academic Emergency Medicine 2003; 10: 684–687.

35.

36.

Holman C, Piper SK, Grittner U, et al. Where Have All the Rodents Gone? The Effects of Attrition in Experimental Research on Cancer and Stroke. PLoS Biol 2016; 14: e1002331.

Abstract

It is a difficult task and a great responsibility to evaluate and manage patients with acute - and potentially life-threatening - clinical presentations. It is even more complex to achieve high standards of care for cases on call. Indeed, on-call gastroenterologists, hepatologists and endoscopists are faced with a wide and protean range of gastrointestinal, liver and pancreatic emergencies. The decision-making process for cases on call is mainly based on information received over the phone, on medical knowledge and clinical experience, and on the resources available. As the degree of confidence in any information given on call may vary, it is of tremendous importance to note, and to document, with precise timing, what has been communicated by, proposed to, and eventually decided with, multiple caregivers (i.e. nurses, emergency physicians, intensive care physicians, surgeons, radiologists etc.)

Topics

Endoscopy Surgery

Citation

Dray X and Marteau P. Mistakes in cases on call and how to avoid them. UEG Education 2017; 17: 30–32

Published

2024

More Like This:

Ian Gralnek on UEG Week 2024

Egle Dieninyte - Misiune

Mistakes in microscopic colitis and how to avoid them

Andreas Münch

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre

Mistakes in cases on call and how to avoid them

Marine Camus